LeonaBio, Inc. (LONA) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
LeonaBio, Inc. (LONA) trades at $7.70 with AI Score 29/100 (Grade F). LeonaBio, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for neurodegenerative diseases. Market cap: $30.4M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: May 6, 2026LONA stock analysis for 2026: Analysts have set a consensus price target of $10.00 for LeonaBio, Inc., suggesting 29.9% upside from the current price of $7.70. The AI MoonshotScore is 29/100, indicating a bearish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
LONA: 2/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
LeonaBio, Inc. (LONA) Healthcare & Pipeline Overview
LeonaBio, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for neurodegenerative diseases like ALS. With ATH-1105 and ATH-1020 in Phase 1 trials, LeonaBio aims to restore neuronal health and slow neurodegeneration, positioning them within the competitive biotechnology landscape.
What Is the Investment Thesis for LONA?
LeonaBio, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's value hinges on the successful development and commercialization of its lead compounds, ATH-1105 and ATH-1020, both currently in Phase 1 clinical trials. Positive clinical data from these trials could serve as a significant catalyst, driving substantial appreciation in the company's $30.4M market capitalization. Key value drivers include the potential to address unmet needs in ALS and other neurodegenerative diseases, the strength of the company's intellectual property, and the ability to secure partnerships for further development and commercialization. However, the investment is subject to significant risks, including clinical trial failures, regulatory hurdles, and competition from larger pharmaceutical companies. The company's high beta of 2.23 reflects the volatility associated with clinical-stage biopharmaceutical companies. Investors should carefully weigh the potential upside against the inherent risks before considering an investment in LeonaBio.
Based on FMP financials and quantitative analysis
LONA Key Highlights
LeonaBio, Inc. is a clinical-stage biopharmaceutical company focused on neurodegenerative diseases.
- The company's lead product candidates, ATH-1105 and ATH-1020, are in Phase 1 clinical trials.
- ATH-1105 targets amyotrophic lateral sclerosis (ALS), addressing a significant unmet medical need.
- ATH-1020 is being developed for the treatment of various neurodegenerative diseases.
- LeonaBio, Inc. has a market capitalization of $30.4M, reflecting its early-stage development.
Who Are LONA's Competitors?
LONA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are LONA's Key Strengths?
Proprietary small molecule therapeutics pipeline.
- Focus on restoring neuronal health.
- Lead compounds in Phase 1 clinical trials.
- Experienced management team.
What Are LONA's Weaknesses?
Early-stage clinical development with high risk of failure.
- Limited financial resources.
- Dependence on successful clinical trial outcomes.
- Small market capitalization.
What Could Drive LONA Stock Higher?
Phase 1 clinical trial results for ATH-1105 in ALS (expected H2 2026).
- Phase 1 clinical trial results for ATH-1020 in neurodegenerative diseases (expected Q1 2027).
- Advancement of preclinical compounds into clinical development.
- Potential strategic partnerships for development and commercialization.
What Are the Key Risks for LONA?
Financial-distress signal — its Altman Z-Score of -15.20 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for ATH-1105 and ATH-1020.
- Regulatory delays or rejection of lead compounds.
- Competition from other companies developing neurodegenerative disease therapeutics.
- Limited financial resources to support clinical development.
- Patent expiration and intellectual property challenges.
What Are the Growth Opportunities for LONA?
- Advancement of ATH-1105 in ALS Treatment: LeonaBio's ATH-1105, currently in Phase 1 trials, targets ALS, a market projected to reach $1.7 billion by 2028. Positive clinical trial results could lead to accelerated development and potential FDA approval, providing a significant revenue stream. The company's focus on restoring neuronal health offers a differentiated approach in a field with limited treatment options, potentially capturing a substantial market share.
- Development of ATH-1020 for Broader Neurodegenerative Diseases: ATH-1020, also in Phase 1, aims to treat various neurodegenerative diseases. The global market for neurodegenerative disease therapeutics is expected to reach $45.8 billion by 2029. Successful clinical trials could expand ATH-1020's application to Alzheimer's, Parkinson's, and other conditions, significantly increasing its market potential and establishing LeonaBio as a key player in the field.
- Expansion of Preclinical Pipeline: LeonaBio's early-stage compounds in preclinical development represent future growth opportunities. These compounds target novel mechanisms of action and address unmet needs in neurodegenerative diseases. Successful preclinical studies could lead to the identification of new drug candidates and the expansion of LeonaBio's pipeline, enhancing its long-term growth prospects and attracting potential partnerships.
- Strategic Partnerships and Collaborations: LeonaBio can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its pipeline assets. Collaborations can provide access to funding, expertise, and global distribution networks, enhancing LeonaBio's ability to bring its therapies to market. These partnerships can also validate the company's technology and increase its visibility within the industry.
- Orphan Drug Designation and Accelerated Approval Pathways: LeonaBio can leverage orphan drug designation and accelerated approval pathways for its lead compounds, particularly ATH-1105 in ALS. Orphan drug designation provides market exclusivity and other incentives, while accelerated approval pathways can expedite the regulatory review process. These strategies can reduce development timelines and costs, increasing the attractiveness of LeonaBio's pipeline and enhancing its competitive position.
What Are LONA's Competitive Advantages?
- Proprietary small molecule therapeutics targeting neurodegeneration.
- Clinical-stage pipeline with ATH-1105 and ATH-1020 in Phase 1 trials.
- Expertise in neuronal health and neurodegenerative disease mechanisms.
- Intellectual property protection for key compounds and technologies.
What Does LONA Do?
LeonaBio, Inc., formerly known as Athira Pharma, Inc., is a clinical-stage biopharmaceutical company dedicated to developing innovative small molecule therapeutics aimed at restoring neuronal health and slowing neurodegeneration. Founded in 2011 and headquartered in Bothell, Washington, LeonaBio is committed to addressing the unmet medical needs of patients suffering from debilitating neurodegenerative diseases. The company's evolution reflects a strategic focus on developing targeted therapies that can modify the course of these complex conditions. LeonaBio's product pipeline features two lead compounds, ATH-1105 and ATH-1020, both currently in Phase 1 clinical trials. ATH-1105 is being developed for the treatment of amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease affecting motor neurons. ATH-1020 is being investigated for the treatment of various neurodegenerative diseases, with the goal of improving cognitive function and overall neurological health. In addition to these clinical-stage assets, LeonaBio has several early-stage compounds in preclinical development, representing future growth opportunities. LeonaBio operates within the highly competitive biotechnology industry, focusing on a targeted approach to neurodegenerative diseases. The company's strategy involves rigorous scientific research, clinical development, and strategic partnerships to advance its pipeline and deliver meaningful therapies to patients.
What Products and Services Does LONA Offer?
- Develop small molecule therapeutics for neurodegenerative diseases.
- Focus on restoring neuronal health and slowing neurodegeneration.
- Conduct Phase 1 clinical trials for ATH-1105 in ALS treatment.
- Conduct Phase 1 clinical trials for ATH-1020 in neurodegenerative diseases.
- Advance early-stage compounds in preclinical development.
- Seek strategic partnerships for development and commercialization.
How Does LONA Make Money?
- Develop and license or sell small molecule therapeutics.
- Generate revenue through partnerships and collaborations.
- Focus on clinical trials to prove efficacy and safety.
- Seek regulatory approvals for commercialization.
What Industry Does LONA Operate In?
LeonaBio, Inc. operates within the biotechnology industry, which is characterized by intense competition, high R&D costs, and stringent regulatory requirements. The market for neurodegenerative disease therapeutics is substantial and growing, driven by an aging population and increasing prevalence of conditions such as Alzheimer's disease, Parkinson's disease, and ALS. LeonaBio's focus on small molecule therapeutics positions it within a segment of the market that is attracting significant investment and innovation. The company competes with both large pharmaceutical companies and smaller biotech firms that are developing novel therapies for neurodegenerative diseases. Success in this industry requires strong scientific expertise, efficient clinical trial execution, and strategic partnerships to navigate the complex regulatory and commercial landscape.
Who Are LONA's Key Customers?
- Patients suffering from neurodegenerative diseases.
- Pharmaceutical companies seeking to expand their portfolios.
- Healthcare providers prescribing treatments for neurological conditions.
Company Profile
LeonaBio, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Bothell, US. The company is led by CEO Mark J. Litton. LONA has traded publicly since 2020.
LeonaBio, Inc. (LONA) Valuation Context
Valued at $30.4M, LONA is classified as a micro-cap stock. Relative to its peer group, LONA's quantitative score of 29/100 is below the peer average of 76/100.
Financial Health
LeonaBio, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -15.20 places it in the distress zone, a signal of elevated financial risk.
Forward Outlook
Wall Street analysts project LeonaBio, Inc. revenue of about $0 for fiscal 2026, with EPS near $-2.57.
LONA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- LeonaBio's recent insider buying suggests confidence from leadership in the company's future, which often indicates potential growth.
- Community sentiment has shown increasing optimism as discussions around their innovative therapies gain traction on social platforms.
- Recent partnerships with research institutions highlight the company's commitment to advancing its technology, enhancing credibility in the biotech space.
- Positive media coverage has spotlighted their unique approach to genetic therapies, attracting interest from both retail and institutional investors.
Bear Case
- Concerns over regulatory hurdles for biotech firms remain prevalent, causing some investors to be cautious about LeonaBio's path to market.
- Recent discussions in the community reflect skepticism regarding the scalability of their technology, which could hinder growth prospects.
- Market sentiment has been influenced by broader economic conditions affecting biotech investments, leading to a more cautious outlook.
- Insider selling activity has raised eyebrows, with some interpreting it as a lack of confidence in the company's short-term performance.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
LONA Latest News
-
12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga · Jun 22, 2026
LONA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for LONA.
Price Targets
Consensus target: $10.00
LONA MoonshotScore
What does this score mean?
The MoonshotScore rates LONA 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Mark J. Litton
CEO
Mark J. Litton serves as the CEO of LeonaBio, Inc., bringing extensive experience in the biopharmaceutical industry. His career spans various leadership roles in both established and emerging companies, with a focus on drug development and commercialization. Litton's background includes a strong foundation in business strategy, corporate finance, and operations. He has a proven track record of driving growth and creating value in the healthcare sector. His expertise is crucial for guiding LeonaBio through its clinical development programs and strategic initiatives.
Track Record: Under Mark Litton's leadership, LeonaBio has focused on advancing its lead compounds, ATH-1105 and ATH-1020, through Phase 1 clinical trials. He has overseen the company's strategic shift following its name change in January 2026, emphasizing a renewed commitment to neurodegenerative disease therapeutics. Litton has also been instrumental in securing funding and building a strong team to support LeonaBio's growth objectives.
LONA Healthcare Stock FAQ
What does the AI Score mean for LONA?
LONA holds an AI Score of 29/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. LeonaBio, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for neurodegenerative diseases. Their pipeline includes ATH-1105 and ATH-1020, both …
What does LeonaBio, Inc. do?
LeonaBio, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for neurodegenerative diseases. The company's lead product candidates, ATH-1105 and ATH-1020, are in Phase 1 clinical trials, targeting amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions. LeonaBio aims to restore neuronal health and slow neurodegeneration, addressing significant unmet medical needs in the treatment of these debilitating diseases.
What do analysts say about LONA stock?
As of May 6, 2026, analyst coverage of LeonaBio, Inc. (LONA) is limited due to its small market capitalization and early-stage clinical development. Current valuations are primarily based on the potential of its lead compounds, ATH-1105 and ATH-1020, to successfully complete clinical trials and gain regulatory approval.
What are the main risks for LONA?
LeonaBio, Inc. faces several significant risks inherent to its business model and industry. The primary risk is the potential failure of its lead compounds, ATH-1105 and ATH-1020, in clinical trials. Clinical trial failures can result in significant financial losses and a decline in the company's stock price.
How does LeonaBio, Inc. navigate regulatory approval processes?
LeonaBio, Inc. navigates regulatory approval processes by adhering to strict guidelines set by regulatory agencies such as the FDA. The company focuses on designing and executing well-controlled clinical trials to generate robust data supporting the safety and efficacy of its drug candidates. LeonaBio also engages with regulatory agencies early in the development process to seek guidance and address potential concerns.
How does LeonaBio, Inc. manage patent expiration risks?
LeonaBio, Inc. manages patent expiration risks through a multi-faceted approach. The company actively seeks to protect its intellectual property by filing patents on its novel compounds, formulations, and methods of use. LeonaBio also pursues strategies to extend the patent life of its products, such as developing new formulations or indications.
What are the key factors to evaluate for LONA?
LeonaBio, Inc. (LONA) holds an AI score of 29/100 (low). Analysts target $10.00 (+30%). presents a high-risk, high-reward investment opportunity within the biotechnology sector. Not financial advice.
How frequently does LONA data refresh on this page?
LONA's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven LONA's recent stock price performance?
LeonaBio, Inc. (LONA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary small molecule therapeutics pipeline. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on limited available data.
- Future clinical trial results may significantly impact the company's valuation.
- Analyst consensus is limited due to the company's small market capitalization.